Articles On Immuron (ASX:IMC)

Highlights Quotation makes newly issued shares tradeable on the ASX Extra tradable supply can influence liquidity and short-term pricing Markets focus on dilution, use of funds, and execution progress Immuron has quote...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX retreats from session highs of +0.63pc to climb +0.30pc Gold and silver stocks recover from recent sell down NAB losses undercut broader gains   Precious metals get a polish The ASX 200 has bounced after closing at a three-week low ye...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX recovers from session lows of -0.91pc to fall -0.13pc Info tech, commodities weakness undercut market Banks, defensive sectors mount resistance ASX battens down the hatches It was looking like we were in for another 90-point routing...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Impedimed and Avita Medical have won a ‘pay rise’ from private and public US payors Orthocell posts record revenue – an entrée perhaps, with US sales main course to come  Gut disorders house Immuron outlines a packed October schedule   Fe...

Amid soaring global tensions, investors have flocked to the best known local defence stocks ASX-listed companies have snared military contracts for goods and services including counter drone services, AI, virtual reality and high-tech lase...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Dimerix boss Dr Nina Webster to join Imagion Biosystems as non-executive director Webster has extensive experience with ASX healthcare companies and is also non-executive chair of SYNthesis BioVentures Appointment comes as Imagion prepares...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Immuron shares surge more than 30% on robust sales of the company’s traveller’s trots prophylactic Visionflex turns cash flow positive In Tetra-theory, this one’s worth a lot more   Wake up folks! It’s mid-July but there’s still only a tr...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

As a former bus driver, Dimerix (ASX:DXB) CEO Dr Nina Webster knows that the drug development journey is just as important as the destination when it comes to delivering value to shareholders. The therapeutic trip can be painfully long, esp...

The US health sector shows signs of stabilising as chaos subsides Immutep will meet with the FDA following “excellent” follow-on trial results When it comes to its sagging share price, Immuron leaves blame-shifting to the defeated Liberals...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Banks fall, mining stocks rise Rio Tinto in mega merger talks, suggests Bloomberg China hits 5pc growth but property struggles   After a day of zigzagging, the ASX closed lower by 0.2% on Friday as losses in the financials and comms secto...

Immuron Ltd (ASX:IMC) has moved through a series of development milestones for its drug Travelan: which aims at preventing contraction of traveller’s diarrhea, a disorder of the digestive tract caused by pathogenic bacteria. The company...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Harvard University’s teaching hospital will adopt Echo IQ’s AI-based aortic stenosis detection tool Immuron trots out its Travelan agenda at its AGM Oncosil goes hot and cold with latest distribution deals   Echo IQ (ASX:EIQ) has won the...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

ASX rises as banking and tech sectors lead gains Arcadium Lithium surges on potential acquisition by Rio Tinto Retail groups urge Reserve Bank to cut rates ahead of holiday sales   The ASX200 index rose by 0.7% on Monday though investors...

    ASX edges down in a quiet market Pilbara Minerals falls 5pc as share block sale is reported Westpac sells auto finance unit for up to $1.6 billion   The ASX has lifted slightly on Thursday, up by 0.1%, as traders remain cautious amid...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

Momentum trading involves buying rising stocks and selling falling ones This works best during economic expansion, when market trends are stronger We take a look at three signals momentum traders use Momentum trading is a popular investme...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

IMM files a pre-IND application with US FDA for IMM-529 targeting common pathogen clostridioides difficile Ansell completes 100% acquisition of the assets of US giant Kimberly-Clark Corporation’s personal protective business Actinogen Xana...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Steve Lydeamore’s advice to biotech peers seeking to do business with the US military is to be armed with a high knowledge readiness level (KRL) when it comes to interpreting acronyms such as … KRL. The head of traveller’s diarrhoea fighter...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. The Relative Strength Index (RSI) is a popular...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. It involves betting that the stock market’s recent winners will remain winners. One of the best known momentum traders in the world is hedge f...

This week’s Bulls N’ Bears top ASX runner is… Macro Metals. Its share price rose more than 166 per cent to join fellow movers and shakers Immuron, Sultan Resources and Dynamic Metals.

Stockhead’s Top 10 at 11, published each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percenta...

The ASX200 closed up 0.4 per cent. Industrials & IT led the ranks – both up more than a per cent – while energy weighed on the market, losing well over 1.1 per cent.   What drove industrials? The standout was a company, Wiseway Gr...

The ASX 200 lifted modestly by +0.2% on Thursday as gains in Tech and Industrial stocks were offset by losses in Energy.  Local traders brushed out dovish comments from Fed Chair Jerome Powell last night. Appearing before Congress, Powell r...

The ASX200 has been trading up 0.18 per cent to just above 7,745 points – not by the nearly half a per cent tipped before the market opened this morning. The Industrials sector has made the greatest gains, edging up close to a per cent a...

07 Mar 2024 - A snapshot of the stocks on the move, featuring Dotz Nano (ASX:DTZ, OTC:DTZNY), Immuron (ASX:IMC; NASDAQ:IMRN) and Avecho Biotechnology (ASX:AVE).

Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, permanent CEO   Immuron almost doubles on Travelan results Immuron (ASX:IMC) jumped by over 80% this mo...

Australian biopharmaceutical company Immuron (ASX: IMC) has released interim topline results from a US-based clinical trial of lead candidate IMM-124E (Travelan) confirming that a single daily dose can be effective in the prevention of mode...

A little-known ASX healthcare stock is setting the bar sky-high today. In morning trade on Thursday, the All Ordinaries Index (ASX: XAO) is up 0.2%, while shares in this biopharmaceutical company just rocketed 96.9% to 13 cents apiece. Th...